Carolina D Schinke, MD

Research Program: Cancer Therapeutics Faculty Rank: Associate Professor Campus: University of Arkansas for Medical Sciences College: College of Medicine Department: Internal Medicine

Cancer Research Interest

• Type of Research: Basic, Clinical

Contact Information

• Email Address: CDSCHINKE@UAMS.EDU
• Profiles Research Networking Software: View Profile

Open Clinical Trials

• “A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received at Least 1 Prior Line of Therapy” (NCT05455320)
• “A Phase II Study of CART-ddBCMA for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma” (NCT05396885)
• “MAGNETISMM-4 A Phase 1b/2, Open Label Umbrella Study of Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) CD3 Bispecific Antibody, in Combination with Other Anti-Cancer Treatments in Participants with Multiple Myeloma” (NCT05090566)

Active Grants

• NIH/Nat. Inst. of General Medical Sciences – 2P20GM109005
  “Therapy-Induced Damage to The Host Bone Marrow as a Promoter Of Treatment Resistance in Multiple Myeloma”
  Principal Investigator
  08/17/20 – 05/31/25

Publications

• Mazahreh F, Mazahreh L, Schinke C, [et al.]. Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis. Blood advances. 2023. PMID: 36857755.
• Al Hadidi S, Dongarwar D, Schinke C, [et al.]. Racial Differences in Spinal Cord Compression Related Hospitalizations in Patients with Multiple Myeloma. Clinical hematology international. 2023. PMID: 36737587.
• Kleman A, Singavi AK, Pommert L, [et al., including Schinke C]. A timeline of genetic variant enrichment: from multiple myeloma diagnosis to myeloma-associated myeloid malignancy. Blood advances. 2023. PMID: 36724511.
• Schinke C, Weinhold N, Delgado-Calle J. Editorial: The role of the bone marrow microenvironment in multiple myeloma evolution and therapy. Frontiers in oncology. 2023 13:1157555. PMID: 36895479. PMCID: PMC9990495.
• Al Hadidi S, Szabo A, Esselmann J, [et al., including Schinke C]. Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy. Bone marrow transplantation. 2022. PMID: 36550200.
• Mohan M, Rein LE, Thalambedu N, [et al., including Schinke C]. Corneal toxicity with belantamab mafodotin: Multi-institutional real-life experience. American journal of hematology. 2022 97(12):E451-E453. PMID: 36097868.
• Al Hadidi S, Dongarwar D, Salihu H, [et al., including Schinke C]. Ethnic Disparities in AL Amyloidosis Outcomes Among Hospitalized Patients in the United States. Clinical hematology international. 2022 4(3):117-120. PMID: 36131130. PMCID: PMC9492819.
• Schinke C, Poos AM, Bauer MA, [et al.]. Characterizing the role of the immune microenvironment in multiple myeloma progression at a single cell level. Blood advances. 2022. PMID: 35977111. PMCID: PMC9647426.
• Rasche L, Schinke C, Maura F, [et al.]. The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states. Nature communications. 2022 13(1):4517. PMID: 35922426. PMCID: PMC9349320.
• Dweik A, Dweik H, Mian H, [et al., including Schinke C]. Gender disparities in multiple myeloma publications. EJHaem. 2022 3(3):966-969. PMID: 36051049. PMCID: PMC9422002.
• Alqazaqi R, Schinke C, Thanendrarajan S, [et al.]. Geographic and Racial Disparities in Access to Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials for Multiple Myeloma. JAMA network open. 2022 5(8):e2228877. PMID: 36018590. PMCID: PMC9419017.
• Gai D, Chen JR, Stewart JP, [et al., including Schinke C]. CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation. The Journal of clinical investigation. 2022. PMID: 35881476. PMCID: PMC9479617.
• Mohan M, Becnel MR, Shah UA, [et al., including Schinke C]. Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience. American journal of hematology. 2022. PMID: 35472167.
• Al Hadidi S, Schinke C, Thanendrarajan S, [et al.]. Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms. JAMA network open. 2022 5(4):e228161. PMID: 35442451. PMCID: PMC9021907.
• Abushukair H, Syaj S, Ababneh O, [et al., including Schinke C]. First- versus second-generation Bruton tyrosine kinase inhibitors in Waldenström's Macroglobulinemia: A systematic review and meta-analysis. American journal of hematology. 2022. PMID: 35358350.
• Larsen K, Spencer H, Mohan M, [et al., including Schinke C]. Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission. Journal of clinical medicine. 2022 11(6). PMID: 35329966. PMCID: PMC8955129.
• Mohan M, Gundarlapalli S, Szabo A, [et al., including Schinke C]. Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma. American journal of hematology. 2022. PMID: 35285981.
• Mikulasova A, Kent D, Trevisan-Herraz M, [et al., including Schinke C]. Epigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancers. Genome research. 2021. PMID: 34933939. PMCID: PMC9341503.
• Baker D, Bimali M, Carrillo L, [et al., including Schinke C]. Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status. Haematologica. 2021 106(12):3215-3218. PMID: 34847659. PMCID: PMC8634177.
• Mohan M, Kendrick S, Szabo A, [et al., including Schinke C]. Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma. Blood advances. 2021. PMID: 34807986. PMCID: PMC8945288.
• Mohan M, Maatman TC, Schinke C. The Role of Monoclonal Antibodies in the Era of Bi-Specifics Antibodies and CAR T Cell Therapy in Multiple Myeloma. Cancers. 2021 13(19). PMID: 34638393. PMCID: PMC8507719.
• Yarlagadda N, Gundarlapalli S, Sharma S, [et al., including Schinke C]. Hematological and infectious complications with CD38 antigen targeting monoclonal antibody-based therapies in multiple myeloma: A meta-analysis of randomized control trials. Leukemia research. 2021 110:106714. PMID: 34598075.
• Baker D, Bimali M, Carrillo L, [et al., including Schinke C]. Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status. Haematologica. 2021. PMID: 34382384.
• Yarlagadda L, Boerma M, Gundarlapalli S, [et al., including Schinke C]. Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma. Cancers. 2021 13(16). PMID: 34439174. PMCID: PMC8392190.
• Boyle EM, Rosenthal A, Ghamlouch H, [et al., including Schinke C]. Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups. Leukemia. 2021. PMID: 34365473.
• Boyle EM, Rosenthal A, Wang Y, [et al., including Schinke C]. High-risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse. British journal of haematology. 2021. PMID: 34244996.
• Mohan M, Szabo A, Yarlagadda N, [et al., including Schinke C]. Persistent bone marrow minimal residual disease as a "high-risk" disease feature in multiple myeloma. American journal of hematology. 2021. PMID: 34050985.
• Schinke CD, Boerma M, Bird JT, [et al.]. PHF19 inhibition as a therapeutic target in multiple myeloma. Current research in translational medicine. 2021 69(3):103290. PMID: 33894670. PMCID: PMC8316274.
• Mohan M, Tackett A, Kumar M, [et al., including Schinke C]. Bone remineralization of lytic lesions in multiple myeloma - The Arkansas experience. Bone. 2021 146:115876. PMID: 33556629. PMCID: PMC8627246.
• Boyle EM, Deshpande S, Tytarenko R, [et al., including Schinke C]. The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma. Nature communications. 2021 12(1):293. PMID: 33436579. PMCID: PMC7804406.
• Mohan M, Yarlagadda N, Szabo A, [et al., including Schinke C]. Clinical Characteristics of Testicular Extramedullary Involvement in Multiple Myeloma. American journal of hematology. 2020. PMID: 33338289.
• Deshpande S, Tytarenko RG, Wang Y, [et al., including Schinke CD]. Monitoring treatment response and disease progression in myeloma with circulating cell-free DNA. European journal of haematology. 2020. PMID: 33107092.
• Choudhury SR, Ashby C, Tytarenko R, [et al., including Schinke C]. The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma. Journal of hematology & oncology. 2020 13(1):108. PMID: 32762714. PMCID: PMC7409490.
• Mason MJ, Schinke C, Eng CLP, [et al.]. Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease. Leukemia. 2020 34(7):1866-1874. PMID: 32060406. PMCID: PMC7326699.
• Schinke C, Boyle EM, Ashby C, [et al.]. Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns. Blood cancer journal. 2020 10(6):70. PMID: 32555163. PMCID: PMC7303180.
• Mohan M, Weinhold N, Schinke C, [et al.]. Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome. British journal of haematology. 2020 189(1):67-71. PMID: 31820442.
• Nalghranyan S, Singh AP, Schinke C. The combination of venetoclax, daratumumab and dexamethasone for the treatment of refractory primary plasma cell leukemia. American journal of hematology. 2020 95(2):E34-E35. PMID: 31709578.
• Nishimura KK, Barlogie B, van Rhee F, [et al., including Schinke C]. Long-term outcomes after autologous stem cell transplantation for multiple myeloma. Blood advances. 2020 4(2):422-431. PMID: 31990333. PMCID: PMC6988393.
• Boyle EM, Ashby C, Tytarenko R, [et al., including Schinke C]. BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020. PMID: 31988198.
• Sridharan A, Schinke CD, Georgiev G, [et al.]. Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemias. Blood advances. 2019 3(23):3962-3967. PMID: 31805192. PMCID: PMC6963234.
• Sawyer JR, Tian E, Walker BA, [et al., including Schinke CD]. An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome. Blood cancer journal. 2019 9(8):62. PMID: 31399558. PMCID: PMC6689064.
• Rasche L, Alapat D, Kumar M, [et al., including Schinke C]. Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma. Leukemia. 2019 33(7):1713-1722. PMID: 30573775. PMCID: PMC6586541.
• Atrash S, Dua I, Buros AF, [et al., including Schinke C]. FRAX is a robust predictor of baseline vertebral fractures in multiple myeloma patients. Bone. 2019 121:134-138. PMID: 30244157.
• Mohan M, Susanibar-Adaniya S, Buros A, [et al., including Schinke C]. Bacteremias following autologous stem cell transplantation for multiple myeloma: Risk factors and outcomes. Transplant infectious disease : an official journal of the Transplantation Society. 2019 21(2):e13052. PMID: 30689291.
• Mehdi SJ, Johnson SK, Epstein J, [et al., including Schinke C]. Mesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytes. British journal of haematology. 2019 184(4):578-593. PMID: 30408155. PMCID: PMC6361704.
• Ashby C, Tytarenko RG, Wang Y, [et al., including Schinke C]. Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of TP53. Oncotarget. 2019 10(7):732-737. PMID: 30774775. PMCID: PMC6366829.
• Rasche L, Kumar M, Gershner G, [et al., including Schinke C]. Lack of Spleen Signal on Diffusion Weighted MRI is associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma: A Link to Extramedullary Hematopoiesis?. Theranostics. 2019 9(16):4756-4763. PMID: 31367255. PMCID: PMC6643447.
• Boyle EM, Ashby C, Wardell CP, [et al., including Schinke C]. The genomic landscape of plasma cells in systemic light chain amyloidosis. Blood. 2018 132(26):2775-2777. PMID: 30446495.
• Morgan GJ, He J, Tytarenko R, [et al., including Schinke C]. Kinase domain activation through gene rearrangement in multiple myeloma. Leukemia. 2018 32(11):2435-2444. PMID: 29654269. PMCID: PMC6224403.
• Rasche L, Angtuaco EJ, Alpe TL, [et al., including Schinke C]. The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma. Blood. 2018 132(1):59-66. PMID: 29784643. PMCID: PMC6034645.
• Schinke C, Qu P, Mehdi SJ, [et al.]. The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 24(12):2913-2919. PMID: 29563136.
• Davies FE, Rosenthal A, Rasche L, [et al., including Schinke CD]. Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma. Haematologica. 2018 103(6):1047-1053. PMID: 29567784. PMCID: PMC6058800.
• Mathur P, Thanendrarajan S, Paydak H, [et al., including Schinke CD]. Cardiovascular complications of multiple myeloma in the elderly. Expert review of cardiovascular therapy. 2017 15(12):933-943. PMID: 29164945.
• Mathur P, Hollowoa B, Lala N, [et al., including Schinke C]. Enterococcus raffinosus infection with atypical hemolytic uremic syndrome in a multiple myeloma patient after autologous stem cell transplant. Hematology reports. 2017 9(3):7094. PMID: 29071054. PMCID: PMC5641830.
• Thanendrarajan S, Tian E, Qu P, [et al., including Schinke C]. The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma. Haematologica. 2017 102(9):e364-e367. PMID: 28550191. PMCID: PMC5685226.
• Rasche L, Chavan SS, Stephens OW, [et al., including Schinke C]. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nature communications. 2017 8(1):268. PMID: 28814763. PMCID: PMC5559527.
• Hoering A, Wang H, Carlton V, [et al., including Schinke C]. The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype. Haematologica. 2017 102(8):e313-e316. PMID: 28522572. PMCID: PMC5541885.
• Mohan M, Buros A, Mathur P, [et al., including Schinke C]. Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease. American journal of hematology. 2017 92(8):739-745. PMID: 28383130.
• Rasche L, Angtuaco E, McDonald JE, [et al., including Schinke C]. Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. Blood. 2017 130(1):30-34. PMID: 28432222. PMCID: PMC5501152.
• Mohan M, Samant RS, Yoon D, [et al., including Schinke C]. Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients With Multiple Myeloma. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2017 32(6):1261-1266. PMID: 28240368. PMCID: PMC5466479.
• McDonald JE, Kessler MM, Gardner MW, [et al., including Schinke C]. Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 23(8):1981-1987. PMID: 27698001. PMCID: PMC5777601.
• Chavan SS, He J, Tytarenko R, [et al., including Schinke C]. Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker. Blood cancer journal. 2017 7(2):e535. PMID: 28234347. PMCID: PMC5386330.
• Mohan M, Fogel B, Eluvathingal T, [et al., including Schinke C]. Gastrointestinal histoplasmosis in a patient after autologous stem cell transplant for multiple myeloma. Transplant infectious disease : an official journal of the Transplantation Society. 2016 18(6):939-941. PMID: 27696648.
• Boota M, Schinke C, Ledoux S, [et al.]. CA-125 secreting IgG kappa multiple myeloma. American journal of hematology. 2016 91(10):E457-8. PMID: 27340819.
• Weinhold N, Ashby C, Rasche L, [et al., including Schinke C]. Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. Blood. 2016 128(13):1735-44. PMID: 27516441. PMCID: PMC5043128.
• Jethava Y, Mitchell A, Zangari M, [et al., including Schinke C]. Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myeloma. Blood cancer journal. 2016 6:e471. PMID: 27635734. PMCID: PMC5056975.
• Bachegowda L, Morrone K, Winski SL, [et al., including Schinke C]. Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia. Cancer research. 2016 76(16):4841-4849. PMID: 27287719. PMCID: PMC5398415.
• Jethava Y, Mitchell A, Zangari M, [et al., including Schinke C]. Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma. Blood cancer journal. 2016 6(7):e453. PMID: 27471869. PMCID: PMC5030385.